Posts

Dr. Joe Larsen of the Biomedical Advanced Research and Development Authority discussed current CBRN threats and BARDA’s role in developing and stockpiling countermeasures.

View Slide Deck

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In this webinar, FreeMind experts discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.

View Slide Deck

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.

In this presentation, we provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

View Slide Deck

In order to maximize your funding potential, all sources of funding must be considered, including the less traditional ones.

The NIH’s R21 mechanism aims to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas the R01 mechanism is more suitable for longer programs of up to 5 years, totaling close to $3,000,000. Other agencies such as the Department of Defense, BARDA, FDA, and NSF also have awards for research in the life sciences.

In this webinar, we share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.

View Slide Deck

Every year, US-based non-dilutive sources of funding award billions of dollars towards clinical stage research in the Life Sciences.

Funding is available for clinical stage funding across scientific fields including Infectious Diseases, Neurosciences, Cardiovascular, and many more. These funds come from multiple Institutes within the NIH, such as NIAID, NIAMS, NIDDK, from BARDA, and from the DOD.

In this webinar, we discuss the process for applying, guidelines, key success components and insight into increasing chances for award.

 

View Slide Deck

Tyler Merkeley, CARB-X co-founder and program director for ASPR’s Biomedical Advanced Research and Development Authority, describes the drivers and next steps in creating a diverse portfolio Powered by CARB-X, one of the world’s largest public-private partnerships dedicated to accelerating development of innovative antibacterial drugs, diagnostics, and devices.